Holen Sie sich die Stockscreener-App
26.87
4.61%
1.185
Handel nachbörslich:
26.92
0.05
+0.19%
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Custom Dashboard Highlights Summit Therapeutics Inc. Price MomentumJuly 2025 Technicals & Reliable Intraday Trade Plans - beatles.ru
Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says - 富途牛牛
Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call - Yahoo Finance
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $33 to $35 - 富途牛牛
Summit Therapeutics Faces Questions Over Its Cash Burn And Future - Finimize
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus - TradingView
Evercore ISI Group Raises Summit Therapeutics PT to $34, Maintains Outperform Rating - AInvest
Summit Therapeutics stock price target raised to $34 by Evercore ISI - Investing.com Canada
Summit Therapeutics Inc. Securities Fraud LawsuitClass Action Opportunity - AInvest
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
Summit Therapeutics Reports Q2 2025 Progress and Financials - TipRanks
Summit Therapeutics Q2 Loss Widens to $0.12 per Share - AInvest
Summit Therapeutics Q2 Adjusted Loss Widens - MarketScreener
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 - Placera.se
Summit Therapeutics Amends Stock Distribution Agreement - TipRanks
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.12 per Share, vs. FactSet Est of $-0.10 - MarketScreener
Summit Therapeutics Inc. SEC 10-Q Report - TradingView
Pattern recognition hints at Summit Therapeutics Inc. upsideFree AI Driven Stock Trend Forecast - Newser
Visual trend scoring systems applied to Summit Therapeutics Inc.Free Weekly Stock Watch With Growth Focus - Newser
Summit Therapeutics Inc. recovery potential after sell offChart Driven Entry Timing for Swing Trades - Newser
Summit Therapeutics Advances in Metastatic Colorectal Cancer Treatment with Phase II Trial - TipRanks
Traders Buy Large Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT) - Defense World
ETFs and Analyst Targets: iShares Russell 1000 Growth ETF has 10% Upside - AInvest
Summit Therapeutics' Flawed Buy Thesis and the Missing Link in Oncology Data - AInvest
Summit Therapeutics: Here Are (Some Of) The Reasons The Buy Thesis Is Flawed (NASDAQ:SMMT) - Seeking Alpha
Published on: 2025-08-05 22:22:23 - Newser
Cwm LLC Increases Position in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Using data tools to time your Summit Therapeutics Inc. exitTrend Analysis for Safer Market Entries - Newser
Using portfolio simulators with Summit Therapeutics Inc. includedTechnical Reversal Setup with Risk Limits - Newser
Best data tools to analyze Summit Therapeutics Inc. stockFast Movement Forecast for Trading Success - Newser
Institutional scanner results for Summit Therapeutics Inc.Volume Spike Detection for Early Breakouts - Newser
Summit Therapeutics Q3 2024 slides: Ivonescimab shows superior PFS vs. pembrolizumab - Investing.com Canada
Published on: 2025-08-04 09:17:43 - metal.it
Summit Therapeutics Skyrockets 7.22% – What’s Fueling This Biotech Surge? - AInvest
Advanced analytics toolkit walkthrough for Summit Therapeutics Inc.Weekly Price Target Forecast and Alerts - Newser
How hedge fund analytics apply to Summit Therapeutics Inc. stockHigh Conviction Stock Long-Term Summary - Newser
How volatile is Summit Therapeutics Inc. stock compared to the marketDiscover breakthrough stocks with expert help - Jammu Links News
Is Summit Therapeutics Inc. stock a growth or value playMarket Liquidity and Price Flow Analysis - Newser
What analysts say about Summit Therapeutics Inc. stockRecord-breaking gains - Jammu Links News
What is Summit Therapeutics Inc. company’s growth strategyBuild a diversified portfolio for steady growth - Jammu Links News
2 Beaten-Down Stocks With Incredible Upside Potential - The Motley Fool
Why is Summit Therapeutics Inc. stock attracting strong analyst attentionTremendous growth opportunities - Jammu Links News
Published on: 2025-08-03 16:05:04 - Jammu Links News
How does Summit Therapeutics Inc. generate profit in a changing economyExtraordinary profit generation - Jammu Links News
Does Summit Therapeutics Inc. stock perform well during market downturnsSuperior return velocity - Jammu Links News
What are the latest earnings results for Summit Therapeutics Inc.Capitalize on market momentum for big wins - Jammu Links News
Can Summit Therapeutics Inc. rally from current levelsLow Drawdown Picks with Weekly Updates - newser.com
Strategies to average down on Summit Therapeutics Inc.Trend Confirmation Scanner with Entry Focus - Newser
Commit To Buy Summit Therapeutics At $18, Earn 30.8% Annualized Using Options - Nasdaq
What’s the recovery path for long term holders of Summit Therapeutics Inc.Free Buy Signal Based on Chart Analysis - Newser
How high can Summit Therapeutics Inc. stock goProfit Target Planning with Exit Confidence - Newser
Advanced analytics toolkit walkthrough for Tyra Biosciences Inc.Free Low Drawdown Real Time Trading Tips - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Is Summit Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSmart Trade Mapping with Entry Details - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Is Summit Therapeutics Inc. stock poised for growthTechnical Setup Guide for Daily Watchlist - Newser
5.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):